Vera Therapeutics Q3 net loss $80.3M; atacicept BLA submission on track for Q4 2025

Vera Therapeutics, Inc.

2025-Q3 EPS reported -$3.27

Net loss $80.3M ($1.26/sh) vs $46.6M ($0.85) in Q3 2024; cash & securities $497.4M.
BLA for atacicept in IgA nephropathy under Accelerated Approval submitted to FDA expected Q4 2025.
ORIGIN 3 36-week results presented as late-breaking oral at ASN Kidney Week on Nov 6, 2025.
PIONEER basket trial and ORIGIN Extend study actively enrolling; initial PIONEER data expected Q4 2025.
Potential FDA approval and U.S. commercial launch of atacicept anticipated in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.